Literature DB >> 25421458

Performance of nonlinear mixed effects models in the presence of informative dropout.

Marcus A Björnsson1, Lena E Friberg, Ulrika S H Simonsson.   

Abstract

Informative dropout can lead to bias in statistical analyses if not handled appropriately. The objective of this simulation study was to investigate the performance of nonlinear mixed effects models with regard to bias and precision, with and without handling informative dropout. An efficacy variable and dropout depending on that efficacy variable were simulated and model parameters were reestimated, with or without including a dropout model. The Laplace and FOCE-I estimation methods in NONMEM 7, and the stochastic simulations and estimations (SSE) functionality in PsN, were used in the analysis. For the base scenario, bias was low, less than 5% for all fixed effects parameters, when a dropout model was used in the estimations. When a dropout model was not included, bias increased up to 8% for the Laplace method and up to 21% if the FOCE-I estimation method was applied. The bias increased with decreasing number of observations per subject, increasing placebo effect and increasing dropout rate, but was relatively unaffected by the number of subjects in the study. This study illustrates that ignoring informative dropout can lead to biased parameters in nonlinear mixed effects modeling, but even in cases with few observations or high dropout rate, the bias is relatively low and only translates into small effects on predictions of the underlying effect variable. A dropout model is, however, crucial in the presence of informative dropout in order to make realistic simulations of trial outcomes.

Mesh:

Year:  2014        PMID: 25421458      PMCID: PMC4287303          DOI: 10.1208/s12248-014-9700-x

Source DB:  PubMed          Journal:  AAPS J        ISSN: 1550-7416            Impact factor:   4.009


  11 in total

1.  Xpose--an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM.

Authors:  E N Jonsson; M O Karlsson
Journal:  Comput Methods Programs Biomed       Date:  1999-01       Impact factor: 5.428

2.  Modelling of pain intensity and informative dropout in a dental pain model after naproxcinod, naproxen and placebo administration.

Authors:  Marcus A Björnsson; Ulrika S H Simonsson
Journal:  Br J Clin Pharmacol       Date:  2011-06       Impact factor: 4.335

3.  A joint model for nonlinear longitudinal data with informative dropout.

Authors:  Chuanpu Hu; Mark E Sale
Journal:  J Pharmacokinet Pharmacodyn       Date:  2003-02       Impact factor: 2.745

4.  PsN-Toolkit--a collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM.

Authors:  Lars Lindbom; Pontus Pihlgren; E Niclas Jonsson; Niclas Jonsson
Journal:  Comput Methods Programs Biomed       Date:  2005-09       Impact factor: 5.428

5.  MMRM vs. LOCF: a comprehensive comparison based on simulation study and 25 NDA datasets.

Authors:  Ohidul Siddiqui; H M James Hung; Robert O'Neill
Journal:  J Biopharm Stat       Date:  2009       Impact factor: 1.051

6.  Modeling and simulation of the time course of asenapine exposure response and dropout patterns in acute schizophrenia.

Authors:  L E Friberg; R de Greef; T Kerbusch; M O Karlsson
Journal:  Clin Pharmacol Ther       Date:  2009-04-22       Impact factor: 6.875

7.  Statistical handling of drop-outs in longitudinal clinical trials.

Authors:  A Heyting; J T Tolboom; J G Essers
Journal:  Stat Med       Date:  1992-12       Impact factor: 2.373

8.  Missing data in longitudinal studies.

Authors:  N M Laird
Journal:  Stat Med       Date:  1988 Jan-Feb       Impact factor: 2.373

9.  Informative dropout modeling of longitudinal ordered categorical data and model validation: application to exposure-response modeling of physician's global assessment score for ustekinumab in patients with psoriasis.

Authors:  Chuanpu Hu; Philippe O Szapary; Newman Yeilding; Honghui Zhou
Journal:  J Pharmacokinet Pharmacodyn       Date:  2011-02-13       Impact factor: 2.745

Review 10.  Modelling placebo response in depression trials using a longitudinal model with informative dropout.

Authors:  Roberto Gomeni; Agnes Lavergne; Emilio Merlo-Pich
Journal:  Eur J Pharm Sci       Date:  2008-11-08       Impact factor: 4.384

View more
  8 in total

1.  Bayesian Individual Dynamic Predictions with Uncertainty of Longitudinal Biomarkers and Risks of Survival Events in a Joint Modelling Framework: a Comparison Between Stan, Monolix, and NONMEM.

Authors:  François Riglet; France Mentre; Christine Veyrat-Follet; Julie Bertrand
Journal:  AAPS J       Date:  2020-02-19       Impact factor: 4.009

2.  Demonstrating Contribution of Components of Fixed-Dose Drug Combinations Through Longitudinal Exposure-Response Analysis.

Authors:  Asbjørn Nøhr-Nielsen; Theis Lange; Julie Lyng Forman; Theodoros Papathanasiou; David J R Foster; Richard N Upton; Ole Jannik Bjerrum; Trine Meldgaard Lund
Journal:  AAPS J       Date:  2020-01-27       Impact factor: 4.009

3.  Nonlinear Mixed-effect Models for Prostate-specific Antigen Kinetics and Link with Survival in the Context of Metastatic Prostate Cancer: A Comparison by Simulation of Two-stage and Joint Approaches.

Authors:  Solène Desmée; France Mentré; Christine Veyrat-Follet; Jérémie Guedj
Journal:  AAPS J       Date:  2015-03-05       Impact factor: 4.009

Review 4.  A review of disease progression models of Parkinson's disease and applications in clinical trials.

Authors:  Charles S Venuto; Nicholas B Potter; E Ray Dorsey; Karl Kieburtz
Journal:  Mov Disord       Date:  2016-05-26       Impact factor: 10.338

5.  Application of Item Response Theory to Model Disease Progression and Agomelatine Effect in Patients with Major Depressive Disorder.

Authors:  Marc Cerou; Sophie Peigné; Emmanuelle Comets; Marylore Chenel
Journal:  AAPS J       Date:  2019-11-12       Impact factor: 4.009

6.  Early predictions of response and survival from a tumor dynamics model in patients with recurrent, metastatic head and neck squamous cell carcinoma treated with immunotherapy.

Authors:  Ignacio González-García; Vadryn Pierre; Vincent F S Dubois; Nassim Morsli; Stuart Spencer; Paul G Baverel; Helen Moore
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2021-02-13

7.  Establishing Good Practices for Exposure-Response Analysis of Clinical Endpoints in Drug Development.

Authors:  R V Overgaard; S H Ingwersen; C W Tornøe
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2015-09-22

8.  Accounting for dropout in xenografted tumour efficacy studies: integrated endpoint analysis, reduced bias and better use of animals.

Authors:  Emma C Martin; Leon Aarons; James W T Yates
Journal:  Cancer Chemother Pharmacol       Date:  2016-05-25       Impact factor: 3.333

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.